Latest eye diseases Stories
LEUVEN, Belgium, February 9 /PRNewswire-FirstCall/ -- - Paper Examines the Potential of Microplasmin to Improve the Treatment of a Range of Back of the Eye Diseases ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require...
Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases.
ST. LOUIS, Nov. 16 /PRNewswire/ -- It's a fact of life that eyes change with age, and baby boomers - Americans born between 1946 and 1964 - are at the stage when many are affected by vision problems.
NEW YORK, Sept.
TARRYTOWN, N.Y., Sept. 14 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc.
A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus), published by Elsevier.
TOKYO, July 31 /PRNewswire/ -- R-Tech Ueno, Ltd.
WALTHAM, Mass., Nov. 5, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
WALTHAM, Mass., Aug. 4, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc.
- Large; stout; burly.